These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 34627328)

  • 21. Anti-CD99 scFv-ELP nanoworms for the treatment of acute myeloid leukemia.
    Vaikari VP; Park M; Keossayan L; MacKay JA; Alachkar H
    Nanomedicine; 2020 Oct; 29():102236. PubMed ID: 32535112
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
    Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
    Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD38-Specific CAR Integrated into CD38 Locus Driven by Different Promoters Causes Distinct Antitumor Activities of T and NK Cells.
    Liao C; Wang Y; Huang Y; Duan Y; Liang Y; Chen J; Jiang J; Shang K; Zhou C; Gu Y; Liu N; Zeng X; Gao X; Tang Y; Sun J
    Adv Sci (Weinh); 2023 Sep; 10(27):e2207394. PubMed ID: 37485647
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD33-Specific Chimeric Antigen Receptor T Cells with Different Co-Stimulators Showed Potent Anti-Leukemia Efficacy and Different Phenotype.
    Li S; Tao Z; Xu Y; Liu J; An N; Wang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
    Hum Gene Ther; 2018 May; 29(5):626-639. PubMed ID: 29409351
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia.
    Cao J; Wang G; Cheng H; Wei C; Qi K; Sang W; Zhenyu L; Shi M; Li H; Qiao J; Pan B; Zhao J; Wu Q; Zeng L; Niu M; Jing G; Zheng J; Xu K
    Am J Hematol; 2018 Jul; 93(7):851-858. PubMed ID: 29633386
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies.
    Watanabe N; Mo F; Zheng R; Ma R; Bray VC; van Leeuwen DG; Sritabal-Ramirez J; Hu H; Wang S; Mehta B; Srinivasan M; Scherer LD; Zhang H; Thakkar SG; Hill LC; Heslop HE; Cheng C; Brenner MK; Mamonkin M
    Mol Ther; 2023 Jan; 31(1):24-34. PubMed ID: 36086817
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery.
    Sommer C; Cheng HY; Nguyen D; Dettling D; Yeung YA; Sutton J; Hamze M; Valton J; Smith J; Djuretic I; Chaparro-Riggers J; Sasu BJ
    Mol Ther; 2020 Oct; 28(10):2237-2251. PubMed ID: 32592688
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
    Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
    Front Immunol; 2021; 12():665970. PubMed ID: 34475869
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.
    Tomuleasa C; Fuji S; Berce C; Onaciu A; Chira S; Petrushev B; Micu WT; Moisoiu V; Osan C; Constantinescu C; Pasca S; Jurj A; Pop L; Berindan-Neagoe I; Dima D; Kitano S
    Front Immunol; 2018; 9():239. PubMed ID: 29515572
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Investigating CD99 Expression in Leukemia Propagating Cells in Childhood T Cell Acute Lymphoblastic Leukemia.
    Cox CV; Diamanti P; Moppett JP; Blair A
    PLoS One; 2016; 11(10):e0165210. PubMed ID: 27764235
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting T-cell malignancies using allogeneic double-negative CD4-CAR-T cells.
    Fang KK; Lee J; Khatri I; Na Y; Zhang L
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37678917
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CAR T-cells targeting FLT3 have potent activity against FLT3
    Jetani H; Garcia-Cadenas I; Nerreter T; Thomas S; Rydzek J; Meijide JB; Bonig H; Herr W; Sierra J; Einsele H; Hudecek M
    Leukemia; 2018 May; 32(5):1168-1179. PubMed ID: 29472720
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor.
    Chen KH; Wada M; Pinz KG; Liu H; Lin KW; Jares A; Firor AE; Shuai X; Salman H; Golightly M; Lan F; Senzel L; Leung EL; Jiang X; Ma Y
    Leukemia; 2017 Oct; 31(10):2151-2160. PubMed ID: 28074066
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CAR T-Cell Therapy in Hematological Malignancies.
    Haslauer T; Greil R; Zaborsky N; Geisberger R
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Kinetics of immune reconstitution after anti-CD19 chimeric antigen receptor T cell therapy in relapsed or refractory acute lymphoblastic leukemia patients.
    Wang Y; Li H; Song X; Qi K; Cheng H; Cao J; Shi M; Yan Z; Jing G; Pan B; Sang W; Wang X; Zhao K; Chen C; Chen W; Zheng J; Li Z; Xu K
    Int J Lab Hematol; 2021 Apr; 43(2):250-258. PubMed ID: 33112046
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inserting EF1α-driven CD7-specific CAR at CD7 locus reduces fratricide and enhances tumor rejection.
    Jiang J; Chen J; Liao C; Duan Y; Wang Y; Shang K; Huang Y; Tang Y; Gao X; Gu Y; Sun J
    Leukemia; 2023 Aug; 37(8):1660-1670. PubMed ID: 37391486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells.
    Ma Q; Garber HR; Lu S; He H; Tallis E; Ding X; Sergeeva A; Wood MS; Dotti G; Salvado B; Ruisaard K; Clise-Dwyer K; John LS; Rezvani K; Alatrash G; Shpall EJ; Molldrem JJ
    Cytotherapy; 2016 Aug; 18(8):985-994. PubMed ID: 27265873
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SECTM1-based CAR T cells enriched with CD7-low/negative subsets exhibit efficacy in CD7-positive malignancies.
    Wei W; Ma H; Yang D; Sun B; Tang J; Zhu Y; Chen X; Huang X; Liu J; Hu Z; Liu T; Zou L; Zhao X
    Blood Adv; 2023 Jul; 7(13):2941-2951. PubMed ID: 36848638
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123.
    Morgan MA; Kloos A; Lenz D; Kattre N; Nowak J; Bentele M; Keisker M; Dahlke J; Zimmermann K; Sauer M; Heuser M; Schambach A
    Viruses; 2021 Jul; 13(7):. PubMed ID: 34372571
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Facts and Challenges in Immunotherapy for T-Cell Acute Lymphoblastic Leukemia.
    Bayón-Calderón F; Toribio ML; González-García S
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081391
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.